However, there is debate about whether treatment with anti-TNFα blockers unmasks preexisting demyelinating disorders such as multiple sclerosis (MS) or induces de novo demyelination of the central nervous system (CNS) and peripheral nervous system. Here, TNF is linked to demyelinating disease.